{"id": 1289207, "name": "Funding for technology - adjuvants and immunomodulators - towards all diseases", "unit": "constant 2024 US$", "createdAt": "2026-07-02T12:11:59.000Z", "updatedAt": "2026-07-02T12:11:59.000Z", "coverage": "", "timespan": "2007-2024", "datasetId": 8029, "shortUnit": "$", "columnOrder": 0, "shortName": "amount__usd__product_adjuvants_and_immunomodulators", "catalogPath": "grapher/neglected_tropical_diseases/2026-06-25/funding/funding_product#amount__usd__product_adjuvants_and_immunomodulators", "dimensions": {"years": {"values": [{"id": 2007}, {"id": 2008}, {"id": 2009}, {"id": 2010}, {"id": 2011}, {"id": 2012}, {"id": 2013}, {"id": 2014}, {"id": 2015}, {"id": 2016}, {"id": 2017}, {"id": 2018}, {"id": 2019}, {"id": 2020}, {"id": 2021}, {"id": 2022}, {"id": 2023}, {"id": 2024}]}, "entities": {"values": [{"id": 355, "name": "World", "code": "OWID_WRL"}]}}, "descriptionShort": "The amount of funding for adjuvants and immunomodulators. This data is expressed in US dollars, adjusted for inflation.", "descriptionProcessing": "- We combined several research technology categories into broader groups: \"Diagnostics\" and \"General diagnostic platforms & multi-disease diagnostics\" are merged into \"Diagnostics and diagnostic platforms\". Additionally \"Biological vector control products\", \"Chemical vector control products\", and \"Fundamental vector control research\" are merged into \"Vector control products and research\".", "type": "int", "grapherConfigIdETL": "019f22be-3897-71d9-a904-70f4a41ff7bf", "datasetName": "G-FINDER", "updatePeriodDays": 365, "datasetVersion": "2026-06-25", "nonRedistributable": false, "display": {"unit": "constant 2024 US$", "shortUnit": "$", "numDecimalPlaces": 0}, "schemaVersion": 2, "processingLevel": "major", "presentation": {"attributionShort": "G-FINDER", "topicTagsLinks": ["Global Health", "Neglected Tropical Diseases"]}, "descriptionKey": ["All reported data is adjusted for inflation using consumer price index (CPI) estimates from the International Monetary Fund (IMF). Any data entered by survey participants in their local currency is converted to USD based on the average annual exchange rate of the relevant financial year.. All figures are in constant 2024 US dollars."], "origins": [{"id": 15624, "titleSnapshot": "G-FINDER", "title": "G-FINDER", "description": "The G-FINDER project tracks annual investment into R&D for new products and technologies to address priority global health challenges. This includes funding for basic research and the development of new drugs, vaccines, diagnostics and other tools for global health priorities that disproportionately affect people in low- and middle-income countries, such as neglected diseases, emerging infectious diseases, and sexual and reproductive health issues.\n\nThe basis of this project is an annual survey of the world's funders and developers of global health R&D. The G-FINDER survey and report series was founded and created by Policy Cures, and has been funded since its inception by the Bill & Melinda Gates Foundation.\n\nThe data collected in this survey has been used to create a unique repository of investment data, providing an unmatched resource for policy-makers, donors, researchers and industry. The database outlines the long-term landscape of funding for R&D for global health priority areas, including where funding gaps exist and how single investments fit into the global picture. This dataset covers the majority of neglected disease, emerging infectious disease, and sexual & reproductive health R&D funding is captured by G-FINDER, because large funders active in this area and target groups identified by our Advisory Committee are typically responsive and, where they are not, are prioritised during survey follow-up.\n\nThe dataset covers major funding for: Neglected Diseases: Bacterial pneumonia & meningitis, Buruli ulcer, Chagas disease, Cryptococcal meningitis, Dengue, Diarrhoeal diseases, Helminth infections (worms & flukes), Hepatitis B, Hepatitis C, Histoplasmosis, HIV/AIDS, Kinetoplastid diseases, Leprosy, Leptospirosis, Malaria, Mycetoma, Rheumatic fever, Salmonella infections, Scabies, Snakebite envenoming, Trachoma, Tuberculosis, Yaws. Emerging Infectious Diseases: Arenaviral haemorrhagic fevers (including Lassa fever), Bunyaviral diseases (including CCHF, RVF, SFTS), Chikungunya, Coronaviral diseases (including MERS, SARS, COVID-19), Emergent non-polio enteroviruses (including EV71, D68), Filoviral diseases (including Ebola, Marburg), Henipaviral diseases (including Nipah), Mpox (monkeypox), Zika. Sexual & Reproductive Health: Contraception, HIV/AIDS, HPV and HPV-related cervical cancer, Multi-purpose prevention technologies, Post-partum haemorrhage, Pre-eclampsia and eclampsia, Sexually transmitted infections.", "producer": "Impact Global Health", "citationFull": "Impact Global Health (2025), G-FINDER data portal, https://gfinderdata.impactglobalhealth.org, accessed 25 June 2026.", "urlMain": "https://gfinderdata.impactglobalhealth.org/pages/data-visualisations/allNeglectedDiseases", "dateAccessed": "2026-06-25", "datePublished": "2025-11-24", "license": {"url": "https://gfinderdata.impactglobalhealth.org/pages/data-visualisations/allNeglectedDiseases", "name": "\u00a9 2026 Impact Global Health Ltd"}}]}